Elsevier

Journal of Hepatology

Volume 26, Issue 2, February 1997, Pages 325-330
Journal of Hepatology

Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis: A prospective, controlled pilot study

https://doi.org/10.1016/S0168-8278(97)80048-7Get rights and content

Abstract

Background: Recently, promising disease modifying effects of low dose corticosteroid treatment in primary biliary cirrhosis have been reported. However, steroid-induced bone loss constitutes a potential drawback of this treatment option.

Aim: To assess whether etidronate can reduce bone loss during corticosteroid treatment.

Methods: Twelve primary biliary cirrhosis patients (all Child-Pugh Class A), treated with prednisone in the context of a 1-year placebo-controlled pilot study with prednisone (maintenance dose 10 mg daily), and azathioprine (50 mg daily), were randomized to receive either cyclical etidronate (400 mg daily, during 2 weeks) alternated with calcium 500 mg daily during 11 weeks or calcium alone. All patients had been receving ursodeoxycholic acid during at least 1 year and this treatment was continued. Bone mass was measured in the lumbar spine and the femoral neck by dual energy X-ray absorptiometry before and after 3 and 12 months of treatment. Markers of bone formation (serum osteocalcin, procollagen-I-propeptide) and bone resorption (urinary deoxypyridinoline and calcium) were also monitored.

Results: The mean lumbar bone mineral density did not significantly change in the patients taking etidronate+calcium, in contrast to patients treated with calcium alone (+0.4 vs. −3.0%; p=0.01). Changes in femoral bone mineral density and markers of bone turnover did not significantly differ between both groups. No adverse effects of etidronate were noted.

Conclusions: Cyclical etidronate apppears to prevent bone loss associated with prednisone treatment in patients with primary biliary cirrhosis. These preliminary results encourage the further evaluation of long term prednisone treatment and concurrent bisphosphonate therapy in primary biliary cirrhosis.

References (34)

  • KD Lindor et al.

    Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference

    Hepatology

    (1995)
  • RP Heaney

    Interpreting trials of bone-active agents

    Am J Med

    (1995)
  • V Locascio et al.

    Bone loss in response to long term glucocorticoid therapy

    Bone Miner

    (1990)
  • S Sherlock et al.
  • R Eastell et al.

    Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis

    Hepatology

    (1991)
  • FHJ Wolfhagen et al.

    Combined treatment with ursodeoxycholic acid and prednisone in primary biliary cirrhosis

    Neth J Med

    (1994)
  • FHJ Wolfhagen et al.

    A randomized, placebo-controlled trial with prednisone/azathioprine in addition to ursodeoxycholic acid in primary biliary cirrhosis [Abstract]

    J Hepatol

    (1994)
  • Cited by (122)

    • The Impact of Tenofovir Disoproxil Fumarate on Reduced Bone Mineral Density and Fractures in Liver Transplant Recipients

      2021, Transplantation Proceedings
      Citation Excerpt :

      Despite the obvious differences in the etiology of liver disease in prior studies, it is also important to note that these studies covered a different era in transplantation regarding immunosuppression and other medications. Differences in rates of fractures may also be explained by the adoption of bisphosphonate therapy as standard of care for osteoporosis by the beginning of our study period [30–32]. We selected a control group consisting of LT recipients with viral hepatitis not taking TDF that included patients with HCV.

    • Glucocorticoid-induced osteoporosis and Cushing’s syndrome

      2020, Marcus and Feldman’s Osteoporosis
    • Glucocorticoid-Induced Osteoporosis

      2013, Osteoporosis: Fourth Edition
    • Osteoporosis in liver cirrhosis

      2012, Gastroenterologia y Hepatologia
    • The Pharmacologic Management of Osteoporosis in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis

      2020, Journal of Clinical Densitometry
      Citation Excerpt :

      We included RCTs of bisphosphonates or hormone replacement therapy (HRT) separately and analyzed different generations of bisphosphonates both together and separately. The 2 studies evaluating etidronate (5,13) were considered “first generation bisphosphonates” while the one study evaluating alendronate (14) was considered a “third generation bisphosphonate.” For our primary outcome of fracture risk, only the etidronate study by Lindor et al (5) and the alendronate study by Zein et al (14) were able to be pooled as there were no events in either arm of the etidronate study by Wolfhagen et al (13) or the HRT study by Ormarsdottir et al (15).

    View all citing articles on Scopus
    View full text